This study will look at how well a measure called the Qmax/eGFR ratio is related to the severity of urination problems in men over the age of 40. Qmax is a test that shows how fast a person can urinate, and eGFR is a number that reflects kidney function. Men who have urinary symptoms will be asked to do a urine flow test, a blood test, and fill out a questionnaire about their symptoms and quality of life. We will study if there is a link between the Qmax/eGFR ratio and how severe their symptoms are. The results may help doctors better understand how kidney and urinary function are related in men with these problems.
This prospective observational study aims to explore the clinical relevance of the Qmax/eGFR ratio in men over 40 years of age presenting with lower urinary tract symptoms (LUTS). Qmax, derived from uroflowmetry, reflects bladder emptying function, while eGFR represents renal filtration capacity. While both parameters are routinely measured in clinical practice, their combined predictive or associative value in LUTS severity has not been well defined. Participants will undergo standard non-invasive assessments including uroflowmetry, serum creatinine testing (for eGFR calculation), and will complete the International Prostate Symptom Score (IPSS) questionnaire. The IPSS includes both total symptom score and quality of life (QoL) component. The primary objective is to evaluate the correlation between the Qmax/eGFR ratio and IPSS total score. Secondary objectives include the relationship between Qmax/eGFR and QoL scores, as well as analysis based on prostate volume categories. This study seeks to identify whether the Qmax/eGFR ratio may serve as a composite marker reflecting both voiding efficiency and renal function in the clinical assessment of LUTS, potentially supporting more individualized decision-making in urological practice.
Study Type
OBSERVATIONAL
Enrollment
100
Correlation Between Qmax/eGFR Ratio and Total IPSS Score
This outcome assesses the statistical correlation between the Qmax/eGFR ratio and the total International Prostate Symptom Score (IPSS). Pearson or Spearman correlation analysis will be used to evaluate the relationship between the ratio and LUTS severity.
Time frame: At baseline
Correlation Between Qmax/eGFR Ratio and IPSS Quality of Life Subscore
This outcome evaluates the correlation between the Qmax/eGFR ratio and the IPSS Quality of Life (QoL) subscore, aiming to assess the association between voiding/renal parameters and patient-perceived well-being.
Time frame: At baseline
Factors Associated With Qmax/eGFR Ratio
This outcome aims to identify clinical factors that may influence the Qmax/eGFR ratio in men over 40 with lower urinary tract symptoms. Variables to be analyzed may include age, prostate volume, voided volume, and average flow rate (Qave), among others. Multivariable analysis will be performed to explore independent associations.
Time frame: At baseline
Association of Clinical Variables With Qmax/eGFR Ratio
This analysis will identify clinical parameters independently associated with Qmax/eGFR ratio, including age, prostate volume, voided volume, and average flow rate (Qave). Multivariable regression models will be used to determine significant predictors.
Time frame: At baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.